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A B S T R A C T
Although the majority of eukaryotic proteins are glycosylated, there is a dearth of knowledge regarding protein sugar
moieties and their changes in disease. Most multiple myeloma cases are characterized by production of monoclonal
immunoglobulins (Ig). We studied galactosylation and sialylation of IgG heavy chains in 16 patients with IgG myeloma
using lectin blotting and densitometry. In comparison to age and sex matched controls, galactosylation was reduced in
multiple myeloma (median 317 vs. 362, range 153–410 vs. 309–447 relative units, p=0.015, Student’s t-test). Sialylation
was stage dependent; samples from patients with stage IIA had lowest amounts of sialic acid, IIIA intermediate and IIIB
highest (142.6 vs. 185.9 vs. 248.5 relative units, correlation coefficient r=0.55). Both galactosylation and sialylation lev-
els were independent of age, sex, treatment type, response to treatment, disease duration and IgG and b2 microglobulin
concentration. These data indicate that multiple myeloma is characterized by aberrant immunoglobulin glycosylation.
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Introduction
Over half of all known proteins contain covalently
linked oligosaccharides and are called glycoproteins1. Be-
cause of the difficulties associated with the study of the
sugar chains of glycoproteins, elucidation of the func-
tional aspects of sugar moieties of glycoproteins lagged
very much behind those of proteins and nucleic acids.
However, development of various sensitive methods for
the analysis of carbohydrate structures has changed the
situation dramatically, and modern science is focusing
more and more on glycoconjugates known to be involved
in many vital physiological processes of multicellular or-
ganisms, from fertilization and development, to modula-
tion of immune functions and memory consolidation2–4.
Their carbohydrate structures undergo specific changes
in many diseases5–8, and the investigation of the sugar
chains formed under pathological states is expected to
provide important data for better understanding of the
underlying mechanisms.
Constant regions of IgG heavy chains are associated
with a population of slightly different oligosaccharides
attached to Asn297 (Figure 1). Specific changes in distri-
bution of these glycoforms were found in several diseases
like rheumatoid arthritis, juvenile rheumatoid arthritis
and lupus erythematosus, but their significance is not
completely understood9–12.
Multiple myeloma is a malignant hemopoietic disease
characterized by clonal proliferation of plasma cells13. In
most cases plasma cells produce and secrete immuno-
globulins and/or immunoglobulin light chains, detectable
as monoclonal peaks on serum electrophoresis or as free
immunoglobulin light chains in urine (Bence-Jones pro-
teins). Because of the production of large quantities of
pathological proteins, multiple myeloma is ideal for stu-
dying glycosylation abnormalities. Studies on very small
numbers of patients indicated that multiple myeloma
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could be associated with changes in IgG glycosylation.
Decreased galactosylation was reported, and initial re-
sults indicated that in some cases oligosaccharide pro-
files of polyclonal IgG reflected the profile of paraprotein
from the same patient, and not that of normal polyclonal
IgG14,15.
We analyzed IgG heavy chain galactosylation and
sialylation in 17 patients with IgG multiple myeloma.
Materials and Methods
Patients and healthy controls
Patients with multiple myeloma were diagnosed ac-
cording to standard criteria13,16, and treated at one of our
institutions. Sixteen consecutively seen patients with
IgG multiple myeloma in various disease phases were in-
cluded in the study. All patients had active disease and
were treated prior to sample collection with polychemo-
therapy. Patients’ characteristics are presented in Table
1. The control group consisted of 19 apparently healthy
volunteers, sex and age matched with the patient group,
chosen from a larger cohort in whom normal galactosy-
lation patterns were studied (Table 1).
The study was performed in accordance with the Dec-
laration of Helsinki. All participants were informed of
the purpose of the study by one of the investigators and
gave oral informed consent.
Clinical and Laboratory Data
The following data were obtained for multiple mye-
loma patients: gender, age, disease type, stage and dura-
tion, IgG and b2-microglobulin concentration. Disease
stage was determined according to the standard Durie
and Salmon criteria15. IgG concentration was measured
using the immunonephelometry method17. b2-microglo-
bulin concentration was measured by a competitive en-
zyme immunoassay (Behring, Marburg, Germany)18.
Preparation of Serum
During venepuncture approximately 9.5 mL of blood
was drawn into Vacutainers (Beckton-Dickinson, Plym-
outh, UK) containing a gel and clot activator. Samples
were left for 1 hour at room temperature to allow clot-
ting, and then centrifuged at 6000 rpm for 20 minutes.
Sera were removed and stored at –20 °C until analysis.
Materials
All chemicals were of analytical grade. Immobilon
PVDF membrane was from Millipore Corp. (Bedford,
MA, USA); bovine serum albumin from Roth (Karlsruhe,
Germany); biotinylated RCA-I lectin from Vector labora-
tories (member of Boehringer Ingelheim Bioproducts
Partnership, Heidelberg, Germany); digoxingenin-labe-
led SNA lectin and anti-digoxigenin Fab fragments la-
beled with alkaline phosphatase from Boehringer Mann-
heim (Mannheim, Germany).
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Fig. 1. The largest neutral biantennary complex oligosaccharide
found at the Fc region of human serum IgG (attached to aspara-
gine (Asn) 297). There is a common pentasaccharide core con-
taining two mannose (Man) residues attached to a b-mannosyl-
di-N-acetylchitobiose unit. Terminal galactose (Gal), sialic acid
(Sia) and bissecting N-acetylglucosamine (GlcNAc) are not pres-
ent on all molecules and their levels vary among individuals.
TABLE 1
CHARACTERISTICS OF PATIENTS AND CONTROLS
Patients Controls
Gender M/F 9 / 7 10 / 9
Age (years) median / range 53 / 43–68 56 / 50–78
Light chain
/ 11 / 5
Stage IIA/IIIA/IIIB 3 / 9 / 4
Disease duration (months) median / range 17 / 1–68
2 microglobulin (mg/L) median / range 2.89 / 1.58–>44 1.0–2.6
IgG (g/L) median / range 28.85 / 6.59–125 9.2–17.5
M – male, F – female
Purification of IgG by anion-exchange
chromatography
Proteins from 0.7 mL of serum were precipitated with
addition of aqueous 4 M ammonium sulfate to final con-
centration of 2,4 M, centrifuged for 5 minutes at 5000
rpm and resuspended in the original volume of 10 mM
potassium phosphate buffer (pH 6.8). Following desalt-
ing on Sephadex (Amersham-Pharmacia, Uppsala, Swe-
den) G25 columns (1.5 ´ 5 cm), the samples were applied
to the anion-exchange column (Fractogel® TMAE-650;
1.5 ´ 3.5 cm, Merck, Darmstadt, Germany), equilibrated
in the 10 mM potassium phosphate buffer (pH 6.8). The
flow rate was 0.2 mL/min. Fractions were analyzed spe-
ctrophotometricaly and collected until the absorbance at
l=280 nm approached baseline. IgG, which eluted as a
first fraction was collected and stored at –20 °C. Other
proteins were eluted with 2 M NaCl, and were not col-
lected. All procedures were performed at room tempera-
ture. Purity of IgG samples was assessed by SDS poly-
acrylamide gel electrophoresis.
Protein estimation
The concentrations of purified IgG fractions were de-
termined spectrophotometricaly at l=280 nm using com-
mercially obtained pure IgG as a standard.
Glycosylation analysis
Heavy and light chains of IgG were separated by dena-
turing polyacrylamide gel electrophoresis19, and trans-
ferred onto PVDF membranes using a semi-dry technic20.
Labeled lectins were used to analyze galactosyla- tion and
sialylation of IgG21. After overnight blocking in 3% BSA,
blots containing electrophoretically separated IgG chains
were incubated with biotinylated galactose- specific RCA-I
lectin, or digoxin-labeled, a(2,6)-sialic acid-specific SNA
lectin. After washing, blots were incubated with strep-
tavidin, or anti-digoxigenin antibodies labeled with alka-
line phosphatase and developed with 0.02 mg/mL 5-bromo-
-4-chloro-3-indolyl phosphate and 0.04 mg/mL nitro-blue
tetrazolium in 50 mM Tris/HCl, pH 9.5, 100 mM NaCl, 5
mM MgCl2.
All samples were analyzed in duplicate and an inter-
nal IgG standard was included into each blot to enable
comparison of samples on different blots. Optical density
of the bands corresponding to IgG heavy-chains was
measured using Ultroscan XL® laser densitometer (Phar-
macia LKB). For maximal precision, two-dimensional
scanning (0.4 mm resolution on the X axis, and 0.2 mm
resolution on the Y axis) was performed. Scans were ana-
lyzed in Gel ScanTM software (Pharmacia LKB). All re-
sults were expressed in absorbance units per mg of IgG.
An example of lectin-blot analysis of IgG heavy chain
sialylation (using SNA lectin from Sambucus nigra) is
shown in Figure 2.
Statistical analysis
The two-tailed heteroscedastic Student’s t-test was
used to measure statistical significance between groups.
A pavlue below 0.05 was considered significant. Trend-
lines were calculated as a least square fit for a linear
equation (ax+b). Population correlation coefficients were
calculated as covariance of two data sets divided by the
product of their standard deviations.
Results
The extent of heavy chain IgG galactosylation was re-
duced in multiple myeloma patients in comparison to
healthy controls (Table 2). The extent of galactosylation
did not correlate with light-chain type, stage, disease du-
ration, IgG or b2-microglobulin concentration (data not
shown).
Although the average level of sialic acid in the multi-
ple myeloma group differed only slightly from the control
group, the variation in levels of sialic acid among pa-
tients with multiple myeloma was higher than in the
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Fig. 2. Multiple myeloma is associated with increased variability in IgG sialylation. Lanes 1–7: IgG from control samples; lane 8: stan-
dard IgG (used to compare results from different blots); lanes 9–14: IgG from patients with multiple myeloma. IgG from control sera
have similar levels of sialic acids, while IgG sialylation in patients with multiple myeloma is more variable.
TABLE 2
GALACTOSYLATION AND SIALYLATION OF IGG HEAVY CHAIN MEASURED IN RELATIVE UNITS
Myeloma patients Controls p (Student’s t-test)
Galactosylation (median / range) 317 (153–410) 362 (309–447) 0.015
Sialylation (median / range) 188.4 (99.7–338.4) 190.8 (169.8–237.6) 0.953
control group (Figure 3). We analyzed the correlation be-
tween sialylation of IgG heavy chain and gender and age
of the patients, duration of the disease, disease stage, IgG
concentration, and concentration of b2-microglobulin.
Disease stage and renal insufficiency correlated with the
increase in sialylation (r=0.40 and 0.48, respectively),
while other analyzed parameters did not. The best pa-
rameter predicting (r=0.55) for increased sialylation was
the combination of disease stage and renal insufficiency
(Figure 4).
In multiple myeloma there was a significant correla-
tion between galactosylation and sialylation of IgG heavy
chains (r=0.63), that was not found in controls (r=0.08).
Discussion
We studied glycosylation of IgG heavy chains in sera
of 16 patients with multiple myeloma and 19 healthy
control individuals. Contrary to previous studies that
used sophisticated glycosylation analysis techniques in
small numbers of patients14,15,22, we determined amounts
of terminal galactose and sialic acids using simple lectin
blotting that can be repeated in most clinical laborato-
ries. In addition we focused on IgG heavy chains to evade
influence of unknown glycosylation of light chains on the
obtained results. Since relatively large amounts of IgG
are needed for this method we were unable to analyze
IgG glycosylation in patients with other types of myelo-
ma (IgA, light chain or non-secretory), who typically
have reduced amounts of IgG.
The small (approximately 15%), but statistically sig-
nificant (p<0.01) decrease of galactose observed (Table
2) is in accordance with results published by Roy Jefferis’
group14,15. This seems to be an inherent characteristic of
multiple myeloma, independent of other, patient or dis-
ease related factors. The same group of authors reported
that the abnormal glycosylation pattern is present also
on polyclonal IgG in myeloma patients. Although these
results were obtained by studying only three patients
and require further confirmation, the hypothesis that
abnormal physiological environment of the bone marrow
caused by a disease may also affect normal plasma cells
producing polyclonal IgG is very attractive.
In contrast to galactosylation, sialylation was depend-
ent on disease stage at diagnosis and renal insufficiency.
These findings are in line with those from a study indi-
cating that the ratio of sialylated to neutral oligosaccha-
rides in monoclonal gammopathy of unknown signifi-
cance (MGUS) is decreased in comparison to multiple
myeloma22, MGUS being a »benign« plasma cell disor-
der23. The influence of renal function on glycosylation of
plasma proteins is unknown. It would be interesting to
see whether sialylation of heavy chain IgG is increased in
persons with other types of renal disease and whether
other protein types show a similar pattern.
The finding, that galactosylation and sialylation are
correlated in samples from patients but not from healthy
controls, suggests that aberrations of sialylation and
galactosylation present in multiple myeloma have a simi-
lar pathogenetic mechanism.
The limitations of this study are obvious: the number
of subjects involved was small, all were treated prior to
sample collection, and disease status and treatment ty-
pes varied considerably. However, since the data on pro-
tein glycosylation in various diseases are extremely lim-
ited, the results are at least interesting, if not definitive.
It seems that patients with multiple myeloma have aber-
rant IgG heavy chain glycosylation. This could, by inter-
fering with normal IgG metabolism and distribution,
contribute to the immunodeficiency characteristic of this
disease. Malignant plasma cells are known to produce
structurally aberrant immunoglobulins24. This could ad-
versely affect its glycosylation. Alternatively, it could be
an effect of bone marrow microenvironment abnormali-
ties caused by aberrant local production of cytokines and
disturbances of cytokine networks. A number of different
cytokines, including interleukin-6, are known to be ab-
normally produced by bone marrow stromal cells in mul-
tiple myeloma25,26. The fact that polyclonal IgG in multiple
myeloma patients have a similar glycosylation pattern as
monoclonal14 seems to favor the latter explanation. Ex-
act mechanisms involved should be the focus of addi-
tional studies including larger number of patients and
using more precise methods for isolation of monoclonal
paraproteins.
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Fig. 3. Distribution of IgG heavy chain sialylation in control and
multiple myeloma patients measured in relative units. Filled
bars – multiple myeloma, Open bars – controls.
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Fig. 4. Increase in stage of multiple myeloma is accompanied with
increased sialylation of IgG heavy chains.
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POREME]AJ GLIKOZILACIJE IgG TE[KOG LANCA U MULTIPLOM MIJELOMU
S A @ E T A K
Iako je ve}ina eukariotskih proteina glikozilirana, nema puno podataka o {e}erima vezanima na proteine niti o
njihovim promjenama u pojedinim bolestima. Multipli mijelom je ve}inom karakteriziran stvaranjem monoklonskih
imunoglobulina (Ig). Istra`ivali smo galaktozilaciju i sijalilaciju IgG te{kog lanca u 16 bolesnika s IgG mijelomom kori-
ste}i specifi~no vezivanje lektina i denzitometriju. U usporedbi s kontrolama podjednake dobi i spola je u multiplom
mijelomu smanjena galaktozilacija (medijan 317 naprema 362, raspon 153–410 naprema 309–447 relativnih jedinica,
p=0.015 koriste}i Studentov t-test). Sijalilacija je ovisila o stadiju. Najmanje sijalinske kiseline je na|eno u uzorcima
bolesnika sa stadijem IIA, ne{to vi{e u onih s IIIA, a najvi{e u IIIB stadiju (142,6 naprema 185,9 naprema 248,5 rela-
tivnih jedinica, koeficijent korelacije r=0,55). Ni razina galaktozilacije niti sijalilacije nisu ovisile o dobi, spolu, vrsti
lije~enja, odgovoru na lije~enje, trajanju bolesti, koncentraciji IgG ili b2 mikroglobulina. Ovi podaci ukazuju da je mul-
tipli mijelom karakteriziran poreme}ajem glikozilacije imunoglobulina.
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